Article thumbnail

Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur

By Marcia Berrêdo-Pinho, Dario E Kalume, Paloma R Correa, Leonardo HF Gomes, Melissa P Pereira, Renata F da Silva, Luiz RR Castello-Branco, Wim M Degrave and Leila Mendonça-Lima
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3094199
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A new twist on an old pathway–accessory Sec [corrected] systems. Mol Microbiol
  2. (2003). A: Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci
  3. (2009). Alderson MR: Identification of Mycobacterium tuberculosis vaccine candidates using human CD4+ T-cells expression cloning. Vaccine
  4. (2005). Alzari PM: Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loopmediated interactions.
  5. (2009). Alzari PM: The FHA-containing protein GarA acts as a phosphorylationdependent molecular switch in mycobacterial signaling.
  6. (2009). BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin
  7. (1927). Bocquet A: Sur la vaccination preventive des enfants nouveau-nés contre la tuberculose par le BCG. Ann Inst Pasteur (Paris)
  8. (2004). Brunak S: Improved prediction of signal peptides:
  9. (2005). Brunak S: Non-classical protein secretion in bacteria.
  10. (2005). Brunak S: Prediction of twinarginine signal peptides.
  11. (2008). CA: Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with
  12. (2005). Castello-Branco LR: BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis–review. Mem Inst Oswaldo Cruz
  13. (2008). Castello-Branco LR: New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. Trans R Soc Trop Med Hyg
  14. Cell wall proteome analysis of Mycobacterium smegmatis strain MC2 155.
  15. (2008). Chemokine receptor-mediated delivery of mycobacterial MPT51 protein efficiently induces antigen-specific T-cell responses. Vaccine
  16. (1996). CK: Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent
  17. (2008). CL: Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis. Expert Opin Biol Ther
  18. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature
  19. (1999). Clements CJ: Issues Relating to the Use of BCG in Immunisation Programmes. A discussion document. Geneva: World Health Organisation. Department of Vaccines and Biologicals;
  20. Coates AR: Multiple moonlighting functions of mycobacterial molecular chaperones. Tuberculosis (Edinb)
  21. (2007). Cole ST: Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA
  22. (1999). Cole ST: Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol
  23. (2001). Cole ST: The evolution of mycobacterial pathogenicity: clues from comparative genomics. Trends Microbiol
  24. (2001). DB: Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nat Med
  25. (1999). Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern.
  26. (1988). Ehrhardt W: Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G250 and R-250. Electrophoresis
  27. (2006). Enhanced patient serum immunoreactivity to recombinant Mycobacterium tuberculosis CFP32 produced in the yeast Pichia pastoris compared to Escherichia coli and its potential for serodiagnosis of tuberculosis.
  28. (2006). Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet
  29. (1994). F: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA
  30. (2002). F: The diversity of acetylated proteins.
  31. (2002). Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun
  32. (2006). FD: Characterization of the twin-arginine translocase secretion system of Mycobacterium smegmatis.
  33. (1992). FM: Immunization of mice with mycobacterial culture filtrate proteins. Clin Exp Immunol
  34. (2009). Functional genomics reveals extended roles of the Mycobacterium tuberculosis stress response factor sigmaH.
  35. (2009). Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCGprimed immunity against Mycobacterium tuberculosis in mice. Vaccine
  36. (2006). Global epidemiology of tuberculosis. Lancet
  37. (2008). HG: Antigen analysis of Mycobacterium tuberculosis H37Rv culture filtrate proteins.
  38. (2007). HG: Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. Proteomics
  39. (2008). HG: High accuracy mass spectrometry analysis as a tool to verify and improve gene annotation using Mycobacterium tuberculosis as an example.
  40. (2008). HG: Membrane and membrane-associated proteins in Triton X-114 extracts of Mycobacterium bovis BCG identified using a combination of gel-based and gel-free fractionation strategies. Proteomics
  41. (2001). High extracellular levels of Mycobacterium tuberculosis glutamine synthetase and superoxide dismutase in actively growing cultures are due to high expression and extracellular stability rather than to a protein-specific export mechanism. Infect Immun
  42. (2000). High resolution electroelution of polyacrylamide gels for the purification of single proteins from Mycobacterium tuberculosis culture filtrate.
  43. (1995). Human T-cell responses to secreted antigen fractions of Mycobacterium tuberculosis. Infect Immun
  44. (2007). Huygen K: Immunogenicity of eight dormancy regulonencoded proteins of Mycobacterium tuberculosis in DNA-vaccinated and tuberculosis-infected mice. Infect Immun
  45. Identification of a novel cytotoxic T lymphocyte epitope from CFP21, a secreted protein of Mycobacterium tuberculosis. Immunol Lett .
  46. (2009). Immunization W-EPo: WHO vaccine-preventable diseases:monitoring system -
  47. (2004). Immunomodulatory action of mycobacterial secretory proteins. Microbes Infect
  48. (2006). In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc
  49. (1991). Isolation and partial characterization of major protein antigens in the culture fluid of Mycobacterium tuberculosis. Infect Immun
  50. (2004). Jungblut PR: CFP10 discriminates between nonacetylated and acetylated ESAT-6 of Mycobacterium tuberculosis by differential interaction. Proteomics
  51. (2003). Kaufmann SH: Comparative proteome analysis of culture supernatant proteins from virulent Mycobacterium tuberculosis H37Rv and attenuated M. bovis BCG Copenhagen. Electrophoresis
  52. (2001). Liberation of soluble proteins from live and dead mycobacterial cells and the implications for pathogenicity of tubercle bacilli hypothesis.
  53. (2006). Lopez-Vidal Y: Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun
  54. (2009). Lopez-Vidal Y: Phenotypic differences between BCG vaccines at the proteome level. Tuberculosis (Edinb)
  55. LopezVidal Y: The secretome of a recombinant BCG substrain reveals differences in hypothetical proteins.
  56. (2004). Manson SR: Asparagine deamidation: a regulatory hourglass. Mech Ageing Dev
  57. (2000). Mapping and identification of Mycobacterium tuberculosis proteins by two-dimensional gel electrophoresis, microsequencing and immunodetection. Electrophoresis
  58. (2009). Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb)
  59. (1993). Marchal G: Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria. Infect Immun
  60. (2007). ML: Long lasting BCG protection against leprosy. Vaccine
  61. (1997). ML: Molecular cloning, purification, and serological characterization of MPT63, a novel antigen secreted by Mycobacterium tuberculosis. Infect Immun
  62. (2001). Novel monoclonal antibodies against major antigens of Mycobacterium bovis.
  63. (2009). Onozaki K: Comparable studies of immunostimulating activities in vitro among Mycobacterium bovis bacillus Calmette-Guerin (BCG) substrains. FEMS Immunol Med Microbiol
  64. (2007). Pevzner PA: Whole proteome analysis of post-translational modifications: applications of mass-spectrometry for proteogenomic annotation. Genome Res
  65. (1999). PM: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science
  66. (2009). Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine
  67. (2005). Proteomics-based consensus prediction of protein retention in a bacterial membrane. Proteomics
  68. (2005). Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Mol Microbiol
  69. (2009). REPORT Global Tuberculosis control Brazil. World Health Organization;
  70. (2009). RW: Mycobacterium tuberculosis Cpn60.2 and DnaK are located on the bacterial surface, where Cpn60.2 facilitates efficient bacterial association with macrophages. Infect Immun
  71. (1975). SM: N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci USA
  72. (2001). Sonnhammer EL: Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes.
  73. (2009). Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog
  74. (2004). Tascon RE: A heterologous DNA priming-Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect Immun
  75. (2007). The Mycobacterium tuberculosis cellsurface glycoprotein apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. J Biol Chem
  76. (2005). TM: The success and failure of BCG - implications for a novel tuberculosis vaccine. Nat Rev Microbiol
  77. (2000). Towards the proteome of Mycobacterium tuberculosis. Electrophoresis
  78. (2005). Translation elongation factor EF-Tu is a target for Stp, a serine-threonine phosphatase involved in virulence of Listeria monocytogenes. Mol Microbiol
  79. (1976). Tuberculin sensitivity in guinea-pigs after vaccination with varying doses
  80. (2008). Tuberculosis Control, Surveillance, Planning, Financing. Geneva: World Health Organization;
  81. (2007). Type VII secretion– mycobacteria show the way. Nat Rev Microbiol
  82. (2008). Wang HH: Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64(190-198)-mtb8.4 in C57/BL6 mice.